Blood culture tests market seen reaching $14.77 billion by 2030

The blood culture tests market is projected to rise from $7.51 billion in 2025 to $8.6 billion in 2026, with further growth to $14.77 billion by 2030, driven by rising bloodstream infections and demand for faster diagnostics. North America led the market in 2025, while automation, molecular testing and AI-supported lab workflows are expected to shape the next phase of expansion.

Why it matters: - Blood culture tests are a core tool for detecting bacteria, yeast and other pathogens in the bloodstream. - The market’s growth reflects rising demand for faster, more accurate diagnosis of infections that can become life-threatening, including bacteremia and septicemia. - The expansion also points to continued investment in hospital labs, automated systems and infection detection tools.

What happened: - The blood culture tests market is projected to grow from $7.51 billion in 2025 to $8.6 billion in 2026. - The forecast implies a 14.5% compound annual growth rate. - The market is expected to reach $14.77 billion by 2030, also at a 14.5% CAGR. - North America held the largest share of the market in 2025. - The market analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report includes a free sample and the full market report.

The details: - Growth in the past period was driven by more bloodstream infections, better hospital laboratory infrastructure, wider use of culture-based diagnostics, antimicrobial resistance concerns and broader access to automated lab instruments. - Future growth is expected to come from stronger demand for faster diagnostic results, wider use of AI-supported lab workflows and advances in molecular testing. - The report points to intensified infection control initiatives and ongoing technological innovation in blood culture analysis. - Key trends include more automated blood culture systems, greater use of molecular diagnostics, improved pathogen identification tools, expanded continuous monitoring platforms and more focus on early sepsis detection. - The company defines blood culture tests as blood examinations used to identify disease-causing microorganisms in the bloodstream. - Infectious diseases are cited as a major growth driver. - The World Health Organization ranks infectious diseases as the second leading cause of death worldwide. - In February 2024, the UK Health Security Agency said tuberculosis cases in England rose to 4,850 in 2023 from 4,380 in 2022, a 10.7% increase.

Between the lines: - The market forecast suggests blood culture testing is moving from a basic lab function toward a more automated, data-driven diagnostic category. - Rising infection rates and sepsis risk are increasing the pressure on healthcare systems to shorten turnaround times. - North America’s lead suggests mature lab infrastructure and adoption of advanced diagnostics are still setting the pace for the industry.

What's next: - The market is likely to see more adoption of automated systems and molecular diagnostics as labs seek faster results. - AI-supported workflows and continuous monitoring platforms are positioned to become more common in blood culture analysis. - Infection-control efforts and early sepsis detection initiatives are likely to keep driving demand through 2030. - The report’s 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, hotspots infographics and updated graphics and tables.

The bottom line: - Blood culture testing is on track for strong double-digit growth as healthcare providers push for quicker, more precise infection diagnosis.